pIR-CMV-SCN2A-Variant-1-IRES-mScarlet Citations (3)

Originally described in: Cryptic prokaryotic promoters explain instability of recombinant neuronal sodium channels in bacteria.
DeKeyser JM, Thompson CH, George AL Jr J Biol Chem. 2021 Jan-Jun;296:100298. doi: 10.1016/j.jbc.2021.100298. Epub 2021 Jan 15. PubMed Journal

---

Articles Citing pIR-CMV-SCN2A-Variant-1-IRES-mScarlet

Articles
Scanning mutagenesis of the voltage-gated sodium channel Na(V)1.2 using base editing. Pablo JLB, Cornett SL, Wang LA, Jo S, Brunger T, Budnik N, Hegde M, DeKeyser JM, Thompson CH, Doench JG, Lal D, George AL Jr, Pan JQ. Cell Rep. 2023 Jun 1;42(6):112563. doi: 10.1016/j.celrep.2023.112563. PubMed
Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders. Berg AT, Thompson CH, Myers LS, Anderson E, Evans L, Kaiser AJE, Paltell K, Nili AN, DeKeyser JL, Abramova TV, Nesbitt G, Egan SM, Vanoye CG, George AL Jr. Brain. 2024 Aug 1;147(8):2761-2774. doi: 10.1093/brain/awae125. PubMed
Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity. Li M, Jin Y, Wu J, Zhao M, Yu K, Yu H. Br J Pharmacol. 2024 Nov;181(21):4311-4327. doi: 10.1111/bph.16496. Epub 2024 Jul 9. PubMed

If you have published an article using this material, please email us at to have your article added to this page.